Sana Biotechnology

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA

Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025.

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at December 2024 Investor Conferences

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

ATTENTION SANA SHAREHOLDERS: Investors who lost money on Sana Biotechnology, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Shareholder Rights Advocates at Levi & Korsinsky Investigate Sana Biotechnology, Inc. (SANA) Regarding Possible Securities Fraud Violations

Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future.

Sana Biotechnology: The Story Becomes Murkier

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANA

NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Levi & Korsinsky Announces an Investigation on Behalf of Sana Biotechnology, Inc. (SANA) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– SANA

Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SANA

Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SANA

Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".

Sana Biotechnology, Inc. Being Investigated on Behalf of Sana Biotechnology, Inc. Investors. Contact Levi & Korsinsky For Details.

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology

Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.

Sana Biotechnology to Present at September 2024 Investor Conferences

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

Sana Biotechnology celebrated the beginning of a new chapter on its journey to make drugs that treat complicated diseases, cutting the ribbon outside the company's new manufacturing facility in Bothell, Wash.

Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle

Sana Biotechnology (NASDAQ: SANA ) just reported results for the first quarter of 2024. Sana Biotechnology reported earnings per share of -32 cents.

SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update.

Sana Biotechnology to Present at May and June 2024 Investor Conferences

Evolus

LifeMD 

Expro Group Holdings NV

Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).

4 Stocks to Keep a Tab on for Amazing Earnings Acceleration

Recursion Pharmaceuticals

Viking Therapeutics

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes

News for Sana Biotechnology Stock (SANA)